Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Interstitial pneumonia during treatment with rituximab

100%
Leś D., Polakiewicz-Gilowska A., Kaleta B., Starzyczny-Słota D., Nowara E.
OncoReview
|
2015
|
vol. 5
|
issue 1
A16-A20
EN
Rituximab (RTX) is a chimeric anti-CD20 antibody. It plays an important role in the treatment of B-cell lymphomas and diseases of autoaggression. RTX-induced lung disease is a rare entity, which should be considered in those patients treated with RTX who present with pulmonary disorders with no clear evidence of infection. A 37-year-old woman suffering from CD20-positive DLBCL (diffuse large B-cell lymphoma) received two cycles of the R-CHOP (RTX, cyclophosphamide, doxorubicin, vincristine and prednisone) regimen. After the second cycle of immunochemotherapy, symptoms of interstitial pneumonia occurred. Having excluded all the other causes, it was diagnosed as a complication associated with the administration of RTX.
2
Publication available in full text mode
Content available

Erythropoietin and the erythropoietin receptor, and drug resistance and progression of the neoplastic disease

100%
Leś D., Saduś-Wojciechowska M., Rutkowski T., Wygoda A., Składowski K.
|
EN
Preclinical studies conducted over the past 10 years have shown that EPO is not only a hormone that regulates erythropoiesis, a major growth factor, but also a cytoplasm with pleiotropic activity that also affects cancer cells. The expression of EPO and its receptor (EPOR) occurs in many cancers of various origins. The EPO/EPOR system is active in many cancer cells and is involved in the modification of molecular signaling pathways and the stimulation of growth, survival, motility and the ability to create metastases. EPO can also increase the resistance of cancer cells in vitro and in vivo to chemotherapy and radiotherapy.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.